SABS — SAB Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $26.21m
- -$13.49m
- $2.24m
- 29
- 31
- 15
- 15
Annual cashflow statement for SAB Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | 20.1 | -17.1 | -18.7 | -42.2 |
| Depreciation | ||||
| Non-Cash Items | 1.46 | 5.96 | -7.65 | 11.1 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -12 | 11.7 | -0.238 | 2.33 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | 10 | 1.99 | -23.5 | -25.1 |
| Capital Expenditures | -12.7 | -10.9 | -2.17 | -0.197 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | 0.009 | — | 0.076 | 0.044 |
| Sale of Fixed Assets | ||||
| Cash from Investing Activities | -12.7 | -10.9 | -2.09 | -0.153 |
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 8.98 | 35.9 | 1.05 | 66.8 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 6.26 | 26.9 | -24.5 | 41.5 |